The protection from the Aβ-challenge achieved with the two SINEUPs appear to involve distinct mechanisms, as only SINEUP-PAN was able to increase Map2, a marker of dendritic microtubules which show aberrations in AD. This evidence concerns the gene MAP2 and Alzheimer disease.